Go Pro

Lyra Therapeutics (LYRA) Institutional Ownership

Lyra Therapeutics logo
$0.28 -0.06 (-17.65%)
As of 08/10/2026 03:28 PM Eastern

Institutional Ownership Changes (13F Filings) for Lyra Therapeutics (NASDAQ:LYRA)

Current
Institutional Ownership
Percentage
95.62%
Number of
Institutional Buyers
(last 12 months)
5
Total
Institutional Inflows
(last 12 months)
$416.81K
Number of
Institutional Sellers
(last 12 months)
1
Total
Institutional Outflows
(last 12 months)
$112.02M
Get LYRA Insider Trade Alerts

Want to know when executives and insiders are buying or selling Lyra Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Chart & View Institutional Buying and Selling Data

LYRA Institutional Buying and Selling by Quarter

Lyra Therapeutics Major Shareholders & Ownership History

Reporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/18/2026Artia Global Partners LP8,756$27K0.0%N/A0.495%
2/17/2026Sabby Management LLC175,158$539K0.8%+37.2%9.896%
2/12/2026DRW Securities LLC16,812$52K0.0%N/A0.947%
11/17/2025Citadel Advisors LLC19,484$128K0.0%N/A1.101%
8/15/2025Perceptive Advisors LLC255,150$2.29M0.2%-98.0%15.558%
8/15/2025Bank of America Corp DE28,542$256K0.0%+33.7%1.740%
8/8/2025Geode Capital Management LLC10,986$98K0.0%-98.9%0.687%
6/27/2025Goldman Sachs Group Inc.370,194$47K0.0%-33.4%27.834%
5/16/2025Goldman Sachs Group Inc.370,194$47K0.0%-33.4%0.559%
2/17/2025Two Sigma Investments LP209,997$43K0.0%-25.7%0.321%
2/17/2025Two Sigma Advisers LP385,500$80K0.0%-16.3%0.589%
2/17/2025BNP Paribas Financial Markets244,920$51K0.0%N/A0.374%
2/14/2025Samsara BioCapital LLC1,965,689$406K0.1%-29.3%3.003%
2/14/2025Northern Trust Corp286,310$59K0.0%+56.2%0.437%
2/13/2025ADAR1 Capital Management LLC533,200$110K0.0%N/A0.815%
2/12/2025Geode Capital Management LLC885,966$183K0.0%+15.3%1.353%
2/12/2025JPMorgan Chase & Co.156,442$32K0.0%+161.8%0.239%
11/15/2024State Street Corp488,720$126K0.0%+88.1%0.747%
8/6/2024Acadian Asset Management LLC985,631$271K0.0%N/A1.617%
7/12/2024Rosalind Advisors Inc.1,034,773$286K0.2%-9.6%1.697%
5/17/2024Ikarian Capital LLC1,056,829$6.57M0.7%-15.7%1.733%
5/10/2024Vanguard Group Inc.1,481,481$9.22M0.0%+38.3%2.430%
4/25/2024Rosalind Advisors Inc.1,144,524$7.12M6.7%-39.4%1.916%
2/15/2024Parkman Healthcare Partners LLC754,885$3.96M0.6%+20.8%1.436%
2/14/2024Vestal Point Capital LP3,000,000$15.72M1.7%N/A5.708%
2/13/2024Armistice Capital LLC1,088,000$5.70M0.1%-29.8%2.070%
2/7/2024Jump Financial LLC16,737$88K0.0%N/A0.032%
1/25/2024Heritage Wealth Management Inc. Texas10,000$52K0.0%N/A0.019%
12/6/2023Citigroup Inc.67,677$265K0.0%N/A0.129%
11/15/2023Armistice Capital LLC1,550,000$6.06M0.1%-61.4%2.949%
11/14/2023Prescott Group Capital Management L.L.C.30,000$117K0.0%N/A0.057%
10/24/2023Bank of New York Mellon Corp18,621$73K0.0%N/A0.038%
8/24/2023Perceptive Advisors LLC12,757,562$52.43M1.5%+39.5%25.747%
8/14/2023Samsara BioCapital LLC2,780,261$11.43M2.0%+56.4%8.733%
8/14/2023Pura Vida Investments LLC1,413,242$5.72M0.8%-29.2%4.439%
8/10/2023Letko Brosseau & Associates Inc.31,900$131K0.0%N/A0.100%
2/15/2023Nantahala Capital Management LLC2,220,830$6.97M0.5%-1.1%6.977%
2/14/2023Pura Vida Investments LLC2,157,298$6.77M0.3%-14.1%6.778%
11/15/2022Pura Vida Investments LLC2,510,302$12.58M0.7%-2.6%7.888%
11/14/2022Boothbay Fund Management LLC34,721$174K0.0%-9.5%0.109%
They didn't warn anyone in 1971. This time someone is warning you. (Ad)

On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel

Request the free guide in 30 seconds and get positioned now
11/10/2022Nantahala Capital Management LLC2,245,830$11.25M0.7%-5.2%17.262%
8/16/2022Pura Vida Investments LLC2,576,196$14.56M0.8%+394.9%19.802%
8/16/2022CVI Holdings LLC60,822$344K0.0%N/A0.468%
8/15/2022Nantahala Capital Management LLC2,369,668$13.39M0.7%N/A18.214%
8/12/2022Ensign Peak Advisors Inc56,229$318K0.0%+43.6%0.432%
8/12/2022Ikarian Capital LLC347,338$1.96M0.4%-17.8%2.670%
5/16/2022Clearline Capital LP119,924$482K0.1%+84.9%0.922%


LYRA Institutional Ownership - Frequently Asked Questions

During the previous two years, 16 institutional investors and hedge funds held shares of Lyra Therapeutics. The most heavily invested institutionals were Perceptive Advisors LLC ($2.29M), Sabby Management LLC ($539K), Samsara BioCapital LLC ($406K), Bank of America Corp DE ($256K), Citadel Advisors LLC ($128K), State Street Corp ($126K), and ADAR1 Capital Management LLC ($110K).Learn more on Lyra Therapeutics' institutional investors.

95.62% of Lyra Therapeutics' stock is owned by institutional investors. Learn more on LYRA's institutional investor holdings.

Of the 11 institutional investors that purchased Lyra Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: ADAR1 Capital Management LLC ($533.20K), BNP Paribas Financial Markets ($244.92K), State Street Corp ($228.90K), Geode Capital Management LLC ($117.58K), Northern Trust Corp ($103.03K), JPMorgan Chase & Co. ($96.68K), and Sabby Management LLC ($47.53K).

Institutional investors have bought a total of 99,776 shares in the last 24 months. This purchase volume represents approximately $416.81K in transactions.

The following institutional investors have sold Lyra Therapeutics stock in the last 24 months: Perceptive Advisors LLC ($12.50M).

Institutional investors have sold a total of 12,502,412 shares in the last 24 months. This volume of shares sold represents approximately $112.02M in transactions.



Institutional ownership data for NASDAQ:LYRA is compiled from quarterly 13F filings submitted to the U.S. Securities and Exchange Commission (SEC), with the most recent received on 2/18/2026. New 13F filings are added each quarter as they're published.
From Our Partners